Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Bellicum Pharmaceuticals, Inc is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the NASDAQ and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 107 staff and has a trailing 12-month revenue of around USD$5.2 million.
Since the stock market crash in March caused by coronavirus, Bellicum Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$2.85, which is 69.02% down on its pre-crash value of USD$9.2 and 147.83% up on the lowest point reached during the March crash when the shares fell as low as USD$1.15.
If you had bought USD$1,000 worth of Bellicum Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$2,669.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,095.58.
|Latest market close||USD$2.85|
|52-week range||USD$0.7211 - USD$12.15|
|50-day moving average||USD$6.3869|
|200-day moving average||USD$6.8156|
|Wall St. target price||USD$17.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.314|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-6.25%|
|1 month (2020-10-30)||-23.18%|
|3 months (2020-08-28)||-53.96%|
|6 months (2020-05-29)||-62.65%|
|1 year (2019-11-29)||228.64%|
|2 years (2018-11-29)||-31.49%|
|3 years (2017-11-29)||-70.77%|
|5 years (2015-11-27)||-87.82%|
|Revenue TTM||USD$5.2 million|
|Gross profit TTM||USD$-55,328,000|
|Return on assets TTM||-50.42%|
|Return on equity TTM||-6120.17%|
|Market capitalisation||USD$32.9 million|
TTM: trailing 12 months
There are currently 444,556 Bellicum Pharmaceuticals shares held short by investors – that's known as Bellicum Pharmaceuticals's "short interest". This figure is 35.8% up from 327,470 last month.
There are a few different ways that this level of interest in shorting Bellicum Pharmaceuticals shares can be evaluated.
Bellicum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Bellicum Pharmaceuticals shares currently shorted divided by the average quantity of Bellicum Pharmaceuticals shares traded daily (recently around 116988.42105263). Bellicum Pharmaceuticals's SIR currently stands at 3.8. In other words for every 100,000 Bellicum Pharmaceuticals shares traded daily on the market, roughly 3800 shares are currently held short.
However Bellicum Pharmaceuticals's short interest can also be evaluated against the total number of Bellicum Pharmaceuticals shares, or, against the total number of tradable Bellicum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellicum Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Bellicum Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.0881% of the tradable shares (for every 100,000 tradable Bellicum Pharmaceuticals shares, roughly 88 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellicum Pharmaceuticals.
Find out more about how you can short Bellicum Pharmaceuticals stock.
We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.
Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 6 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.
Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $0.7211 up to $12.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.85. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.